• Irritable Bowel Syndrome (IBS)
  • Chronic irritable colon
  • Spastic constipation
  • Mucous colitis
  • Abdominal cramps and intestinal spasms

Typical Adult Dosage:

  • 135 mg tablet, 3 times daily, 20 minutes before meals
  • Sustained-release (SR): 200 mg, twice daily
  • Immediate-release tablets: 135 mg
  • Extended-release capsules: 200 mg
  • Take before meals with a full glass of water
  • Do not crush or chew SR capsules
  • Consistency is key for symptom control in IBS
  • Class: Antispasmodic (non-atropinic)
  • Mechanism:
    • Directly relaxes GI smooth muscles via calcium channel blockade
    • No central anticholinergic effects
    • Helps regulate bowel motility without reducing normal peristalsis
  • Mostly acts locally in the GI tract
  • Generally well tolerated
  • Rare and mild:
    • Nausea
    • Dizziness
    • Allergic skin reactions (rash, urticaria)
  • Known hypersensitivity to mebeverine or ingredients
  • Paralytic ileus
  • Minimal interaction risk
  • Can be safely co-administered with:
    • Antibiotics, probiotics, digestive enzymes
    • Psyllium or laxatives in IBS-C

                                   Drug Status

Availability
Pregnancy
Breastfeeding
Schedule
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Duspatalin 135mg Tablet 50’s Abbott Labs Harley’s Ltd
Duspatalin 200mg Capsule 30’s Abbott Labs Harley’s Ltd